DOCSLIB.ORG

The DAG-Responsive C1 Domain As a Drug Target: Structure- Activity and in Vitro Pharmacology of Isophthalate Derivatives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The DAG-Responsive C1 Domain As a Drug Target: Structure- Activity and in Vitro Pharmacology of Isophthalate Derivatives Division of Pharmacology and Toxicology Faculty of Pharmacy University of Helsinki Finland The DAG-responsive C1 domain as a drug target: structure- activity and in vitro pharmacology of isophthalate derivatives Virpi Talman ACADEMIC DISSERTATION To be presented, with the permission of the Faculty of Pharmacy, University of Helsinki, for public examination in auditorium 1041, Viikki Biocenter 2, on November 22nd 2013, at 12 noon. Supervisors Professor Raimo K. Tuominen Division of Pharmacology and Toxicology Faculty of Pharmacy University of Helsinki Finland Dr Elina Ekokoski Division of Pharmacology and Toxicology Faculty of Pharmacy University of Helsinki Finland Current address: Finnish Safety and Chemicals Agency Helsinki, Finland Reviewers Professor Jyrki Kukkonen Department of Veterinary Biosciences Faculty of Veterinary Medicine University of Helsinki Finland Adj. professor Päivi Koskinen Department of Biology University of Turku Finland Opponent Professor Kid Törnquist Department of Biosciences/Cell Biology Åbo Akademi University Finland © Virpi Talman ISBN 978-952-10-9408-8 (paperback) ISBN 978-952-10-9409-5 (PDF) ISSN 1799-7372 Unigrafia - Helsinki University Print Helsinki 2013 “Research is the process of going up alleys to see if they are blind.” - Marston Bates - CONTENTS 1. INTRODUCTION .......................................................................................................................................... 1 2. REVIEW OF THE LITERATURE ...................................................................................................................... 3 2.1 DIACYLGLYCEROL (DAG) SIGNALLING ......................................................................................................... 3 2.2 PROTEIN KINASE C (PKC), THE PRIMARY DAG EFFECTOR............................................................................ 4 2.2.1 PKC family members and domain structure ........................................................................................ 4 2.2.2 Structure and function of PKC C1 domains .......................................................................................... 5 2.2.3 Regulation of PKC activity .................................................................................................................... 7 2.2.4 PKC-mediated signal transduction ....................................................................................................... 9 2.3 OTHER DAG EFFECTORS ............................................................................................................................ 11 2.3.1 Protein kinase D (PKD) ....................................................................................................................... 11 2.3.2 Diacylglycerol kinases (DGKs) ............................................................................................................ 13 2.3.3 Myotonic dystrophy kinase-related Cdc42-binding kinases (MRCKs) ................................................ 14 2.3.4 Munc13 proteins ................................................................................................................................ 15 2.3.5 Chimaerins ......................................................................................................................................... 17 2.3.6 Ras guanyl-releasing proteins (RasGRPs) .......................................................................................... 18 2.4 POTENTIAL THERAPEUTIC INDICATIONS FOR DAG EFFECTOR-TARGETED DRUGS ................................... 18 2.4.1 Cancer ................................................................................................................................................ 19 2.4.2 Alzheimer’s disease (AD).................................................................................................................... 21 2.4.3 Other therapeutic indications ............................................................................................................ 23 2.5 C1 DOMAIN LIGANDS ................................................................................................................................ 25 2.5.1 Phorbol esters and phorbol derivatives ............................................................................................. 25 2.5.2 Bryostatins and their synthetic analogues ........................................................................................ 26 2.5.2 Ingenol derivatives ............................................................................................................................. 27 2.5.3 DAG lactones ..................................................................................................................................... 28 2.5.4 Indolactams and benzolactams ......................................................................................................... 28 2.5.5 Other C1 domain ligands ................................................................................................................... 29 3. AIMS OF THE STUDY ................................................................................................................................. 30 4. MATERIALS AND METHODS ...................................................................................................................... 31 4.1 DRUGS ....................................................................................................................................................... 31 4.2 PRODUCTION AND PURIFICATION OF RECOMBINANT PROTEINS ............................................................ 32 4.2.1 Production of PKCα, PKCδ and β2-chimaerin in Sf9 insect cells (I, III)................................................ 32 4.2.2 Preparation of Sf9 cell homogenates (I, III) ....................................................................................... 32 4.2.3 Production of the C1 domain of MRCKα in E. coli (III) ........................................................................ 32 4.2.4 Purification the C1 domain of MRCKα (III) ......................................................................................... 32 4.3 PHORBOL ESTER DISPLACEMENT ASSAYS ................................................................................................. 33 4.3.1 Filtration method for [3H]PDBu binding (I, III, IV) .............................................................................. 33 4.3.2 Centrifugation method for [3H]PDBu binding (I, III) ........................................................................... 33 4.4 CELL CULTURE (I-IV) .................................................................................................................................. 33 4.4.1 RNA interference (III) ......................................................................................................................... 34 4.5 CELL VIABILITY AND PROLIFERATION ASSAYS ........................................................................................... 34 4.5.1 LDH assay (II) ..................................................................................................................................... 34 4.5.2 MTT assay (II, III) ................................................................................................................................ 35 4.5.3 Thymidine incorporation assay (II) .................................................................................................... 35 4.5.4 Cell proliferation and morphology analysis with Cell-IQ® (II, III, IV) ................................................... 35 4.6 WESTERN BLOTTING ................................................................................................................................. 36 4.6.1 Sample preparation (I-IV) .................................................................................................................. 36 4.6.2 Protein separation and detection (I-IV) ............................................................................................. 36 4.7 IMMUNOCYTOCHEMISTRY AND FLUORESCENCE MICROSCOPY (III) ........................................................ 37 4.8 GENOME-WIDE GENE EXPRESSION ANALYSIS (III, IV) ............................................................................... 38 4.9 STATISTICAL ANALYSIS (I-IV) ..................................................................................................................... 38 5. RESULTS ................................................................................................................................................... 39 5.1 STRUCTURE-ACTIVITY RELATIONSHIP STUDIES ON ISOPHTHALATE DERIVATIVES (I, III) .......................... 39 5.1.1 Binding to the C1 domain of PKC (I) ................................................................................................... 39 5.1.2 Binding affinity constants for PKCα and PKCδ (I) ............................................................................... 39 5.1.3 Binding to other DAG effectors (III) ................................................................................................... 40 5.1.4 Effects on ERK1/2 signalling in HeLa cells (I) ..................................................................................... 41 5.2 EFFECTS OF ISOPHTHALATE DERIVATIVES IN HELA CELLS (II, III) .............................................................. 42 5.2.1 Viability and proliferation (II)............................................................................................................
Load more

Recommended publications
  • Expression and Localization of Grass Carp Pkc-Θ (Protein Kinase C Theta) Gene After Its Activation T
    Fish and Shellfish Immunology 87 (2019) 788–795 Contents lists available at ScienceDirect Fish and Shellfish Immunology journal homepage: www.elsevier.com/locate/fsi Full length article Expression and localization of grass carp pkc-θ (protein kinase C theta) gene after its activation T ∗∗ Rumana Mehjabina,b,1, Liangming Chena,b,1, Rong Huanga, , Denghui Zhua,b, Cheng Yanga,b, ∗ Yongming Lia, Lanjie Liaoa, Libo Hea, Zuoyan Zhua, Yaping Wanga, a State Key Laboratory of Freshwater Ecology and Biotechnology, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, 430072, China b University of Chinese Academy of Sciences, Beijing, 100049, China ARTICLE INFO ABSTRACT Keywords: Haemorrhagic disease caused by grass carp reovirus (GCRV) can result in large-scale death of young grass carp, Grass carp leading to irreparable economic losses that seriously affect large-scale breeding. Protein kinase C (PKC, also Grass carp reovirus (GCRV) known as PRKC) represents a family of serine/threonine protein kinases that includes multiple isozymes in many Protein kinase C (PKC) species. Among these, PKC-θ (PKC theta, also written as PRKCQ) is a novel isoform, mainly expressed in T cells, Host immune defences that is known to be involved in immune system function in mammals. To date, no research on immunological functions of fish Pkc-θ has been reported. To address this issue, we cloned the grass carp pkc-θ gene. Phylogenetic and syntenic analysis showed that this gene is the most evolutionarily conserved relative to zeb- rafish. Real-time quantitative PCR (RT-qPCR) indicated that pkc-θ was expressed at high levels in the gills and spleen of healthy grass carp.
    [Show full text]
  • PKC-Theta-Mediated Signal Delivery from Thetcr/CD28 Surface Receptors
    REVIEW ARTICLE published: 22 August 2012 doi: 10.3389/fimmu.2012.00273 PKC-theta-mediated signal delivery from theTCR/CD28 surface receptors Noah Isakov1* and Amnon Altman2 1 The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences and the Cancer Research Center, Ben-Gurion University of the Negev, Beer Sheva, Israel 2 Division of Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA Edited by: Protein kinase C-theta (PKCθ) is a key enzyme inT lymphocytes, where it plays an important Nick Gascoigne, Scripps Research role in signal transduction downstream of the activated T cell antigen receptor (TCR) and Institute, USA the CD28 costimulatory receptor. Interest in PKCθ as a potential drug target has increased Reviewed by: following recent findings that PKCθ is essential for harmful inflammatory responses medi- Balbino Alarcon, Consejo Superior de Investigaciones Cientificas, Spain ated byTh2 (allergies) andTh17 (autoimmunity) cells as well as for graft-versus-host disease Salvatore Valitutti, INSERM, France (GvHD) and allograft rejection, but is dispensable for beneficial responses such as antiviral *Correspondence: immunity and graft-versus-leukemia (GvL) response. TCR/CD28 engagement triggers the Noah Isakov, The Shraga Segal translocation of the cytosolic PKCθ to the plasma membrane (PM), where it localizes at Department of Microbiology and the center of the immunological synapse (IS), which forms at the contact site between an Immunology, Faculty of Health Sciences and the Cancer Research antigen-specificT cell and antigen-presenting cells (APC). However, the molecular basis for Center, Ben-Gurion University this unique localization, and whether it is required for its proper function have remained of the Negev, P.O.
    [Show full text]
  • Novel Roles of SH2 and SH3 Domains in Lipid Binding
    cells Review Novel Roles of SH2 and SH3 Domains in Lipid Binding Szabolcs Sipeki 1,†, Kitti Koprivanacz 2,†, Tamás Takács 2, Anita Kurilla 2, Loretta László 2, Virag Vas 2 and László Buday 1,2,* 1 Department of Molecular Biology, Institute of Biochemistry and Molecular Biology, Semmelweis University Medical School, 1094 Budapest, Hungary; [email protected] 2 Institute of Enzymology, Research Centre for Natural Sciences, 1117 Budapest, Hungary; [email protected] (K.K.); [email protected] (T.T.); [email protected] (A.K.); [email protected] (L.L.); [email protected] (V.V.) * Correspondence: [email protected] † Both authors contributed equally to this work. Abstract: Signal transduction, the ability of cells to perceive information from the surroundings and alter behavior in response, is an essential property of life. Studies on tyrosine kinase action fundamentally changed our concept of cellular regulation. The induced assembly of subcellular hubs via the recognition of local protein or lipid modifications by modular protein interactions is now a central paradigm in signaling. Such molecular interactions are mediated by specific protein interaction domains. The first such domain identified was the SH2 domain, which was postulated to be a reader capable of finding and binding protein partners displaying phosphorylated tyrosine side chains. The SH3 domain was found to be involved in the formation of stable protein sub-complexes by constitutively attaching to proline-rich surfaces on its binding partners. The SH2 and SH3 domains have thus served as the prototypes for a diverse collection of interaction domains that recognize not only proteins but also lipids, nucleic acids, and small molecules.
    [Show full text]
  • Role of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers
    Review Role of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers Angelo Agathanggelou, Wendy N. Cooper, and Farida Latif Section of Medical and Molecular Genetics, Division of Reproductive and Child Health, The Institute of Biomedical Research, University of Birmingham, Edgbaston, Birmingham, United Kingdom Abstract renal cell carcinomas was identified from region 3p25 confirming In recent years, the list of tumor suppressor genes (or this hypothesis (3). This prompted the search for TSGs within the candidate TSG) that are inactivated frequently by epigenetic other regions of 3p. An important TSG was suspected to reside in events rather than classic mutation/deletion events has been 3p21.3 because instability of this region is the earliest and most growing. Unlike mutational inactivation, methylation is frequently detected deficiency in lung cancer. Overlapping homo- reversible and demethylating agents and inhibitors of histone zygous deletions in lung and breast tumor cell lines reduced the deacetylases are being used in clinical trails. Highly sensitive critical region in 3p21.3 to 120 kb and this region was found to be and quantitative assays have been developed to assess exceptionally gene rich. From this critical region, eight genes were methylation in tumor samples, early lesions, and bodily fluids. identified, including CACNA2D2, PL6/placental protein 6, CYB561D2/101F6, TUSC4/NPRL2/G21, ZMYND10/BLU, RASSF1/ Hence, gene silencing by promoter hypermethylation has potential clinical benefits in early cancer diagnosis, prognosis, 123F2, TUSC2/FUS1, and HYAL2/LUCA2. However, despite extensive treatment, and prevention. The hunt for a TSG located at genetic analysis in lung and breast tumors, none of these candidate 3p21.3 resulted in the identification of the RAS-association genes were frequently mutated.
    [Show full text]
  • Protein Kinase C: the “Masters” of Calcium and Lipid
    Downloaded from http://cshperspectives.cshlp.org/ on September 27, 2021 - Published by Cold Spring Harbor Laboratory Press Protein Kinase C: The “Masters” of Calcium and Lipid Peter Lipp1 and Gregor Reither2 1Institute for Molecular Cell Biology, Medical Faculty, Saarland University, Homburg/Saar, Germany 2Cell Biology and Biophysics Unit, EMBL, Heidelberg, Germany Correspondence: [email protected] The coordinated and physiological behavior of living cells in an organism critically depends on their ability to interact with surrounding cells and with the extracellular space. For this, cells have to interpret incoming stimuli, correctly process the signals, and produce meaning- ful responses. A major part of such signaling mechanisms is the translation of incoming stimuli into intracellularly understandable signals, usually represented by second messen- gers or second-messenger systems. Two key second messengers, namely the calcium ion and signaling lipids, albeit extremely different in nature, play an important and often syner- gistic role in such signaling cascades. In this report, we will shed some light on an entire family of protein kinases, the protein kinases C, that are perfectly designed to exactly decode these two second messengers in all of their properties and convey the signaling content to downstream processes within the cell. nce generated, second messengers relay phosphorylation of additional signaling part- Otheir information content in a plethora ners or effector proteins. We will briefly intro- of properties, including time, quantity (i.e., duce the PKC subfamilies with particular concentration), space (i.e., subcellular distribu- emphasis on their signaling ability, discuss the tion), and interestingly into any combination of important sensing domains, and their proper- these three characteristics.
    [Show full text]
  • Ghazi Rahman Final Phd Dis
    Identification of the Activator Binding Residues in the Second Cysteine-Rich Regulatory Domain of Protein Kinase C Theta (PKCθ) A Dissertation Submitted to The Department of Pharmacological and Pharmaceutical Sciences College of Pharmacy University of Houston In Partial Fulfillment of The Requirements for the Degree of Doctor of Philosophy By Ghazi Muhammad Sayedur Rahman May 2012 “For my parents, brothers and my loving wife and their dreams” iii ACKNOWLEDGEMENTS I would like to thank my Ph.D. advisor Dr. Joydip Das for his inspiration, patience and guidance throughout the time of my dissertation. I had been through difficult times during the course of my graduate studies, which sometimes made me vulnerable, but Dr. Das has never stopped encouraging me to do the right things at right moment. He made me who I am today. As a graduate advisor he has always been methodical and perfectionist. I remember during writing the manuscript on my dissertation work, we talked a lot on what to write, how to write, what figures and tables to be incorporated and how should it be. He has been totally thorough on writing styles, on fine details of every piece of figures and illustrations and tables. He made me to change in the figures and illustrations and putting the right words in places over and over again until he finds the piece of work is absolutely perfect. Dr. Das is an excellent researcher and his passion for science is undoubtedly beyond comparison. He always told me to make one step at a time and guided me through the whole time towards the final goal.
    [Show full text]
  • The C1 Domain in Cancer Signaling Molecules: Regulation by Lipids and Protein-Protein Interactions
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Spring 2010 The C1 Domain in Cancer Signaling Molecules: Regulation by Lipids and Protein-Protein Interactions Hongbin Wang University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Pharmacology, Toxicology and Environmental Health Commons Recommended Citation Wang, Hongbin, "The C1 Domain in Cancer Signaling Molecules: Regulation by Lipids and Protein-Protein Interactions" (2010). Publicly Accessible Penn Dissertations. 141. https://repository.upenn.edu/edissertations/141 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/141 For more information, please contact [email protected]. The C1 Domain in Cancer Signaling Molecules: Regulation by Lipids and Protein- Protein Interactions Abstract Cysteine-rich (C1) domains, present in PKC isozymes, Chimaerins, RasGRPs, PKDs, Munc13s, DGKs, and MRCKs, can bind the diacylglycerol (DAG) second messenger. In the present thesis research, I demonstrated that p23/Tmp21 acts as a C1-domain docking protein that mediates perinuclear translocation of beta2-chimaerin. Glu227 and Leu248 in the beta2-chimaerin C1-domain are crucial for binding p23/Tmp21 and perinuclear targeting. Isolated C1-domains from individual PKC isozymes or RasGRP1 differentially interact with p23/Tmp21. PKCepsilon interacts with p23/Tmp21 specifically via its C1b domain, however this association is lost in response to phorbol esters. These results demonstrate that p23/Tmp21 acts as an anchor that distinctively modulates compartmentalization of C1-domain- containing proteins, and it plays an essential role in beta2-chimaerin re-localization to the perinuclear region in response to phorbol esters. It has been established that apoptosis induced by phorbol esters in LNCaP cells is primarily mediated by the novel PKCdelta.
    [Show full text]
  • A) Analysis of the Ncrnas of Arabidopsis Inflorescences and Pollen Bioreplicates (Two Bioreplicates for Each Tissue
    Supplementary Material: Supplemental Figure 1. (A) Analysis of the ncRNAs of Arabidopsis inflorescences and pollen bioreplicates (two bioreplicates for each tissue). Biological replicates 1 and 2 of inflorescence are paired samples for both pollen biological replicates 1 and 2. (B) Individual tRF accumulation profiles for the different sRNA libraries used in Figure 1C. (C-D) Distribution of 5’ end nucleotide of 19 nt sRNAs along mature tRNA transcript sequences post- transcriptionally modified with the CCA sequence, in inflorescence (C) and pollen (D). Supplemental Figure 2. (A-C) Distribution of 5’ end nucleotide of 19 nt tRFs along mature tRNA transcript sequences post-transcriptionally modified with the CCA sequence in rice (A) and maize (B) pollen, and Physcomitrella patens gametophote-sporophyte (C) samples. Supplemental Figure 3. (A) Individual tRF accumulation profiles for the different sRNA libraries used in Figure 3A. (B) tRF accumulation profile in seedling sRNA libraries from ddm1 (red) and wt (blue), normalized in RPM. (C) Distribution of 19 nt tRFs along mature tRNA transcript sequences post- transcriptionally modified with the CCA sequence in the ddm1 background. (D) tRF accumulation profile in inflorescence sRNA libraries from met1 single and ddc triple mutants. 1 Supplemental Figure 4. (A) Individual tRF accumulation profiles for the different sRNA libraries used in Figure 4B. (B) AGO1-immunoprecipitated tRF accumulation size profile in wt and ddm1. (C) NcRNA categorization of the AGO1-immunoprecipitated sRNAs in wt and ddm1 libraries. (D) RT-PCR analysis of the accumulation of tRNA transcripts in gene-specific reverse (1) or oligo-dT (2) primers synthesized cDNA for selected tRNAs in the ddm1, ddm1/dcl1-11 and ddm1/ago1-24 backgrounds.
    [Show full text]
  • Is a Key Regulator of T-Cell Behavior and a Drug Target for T Cell
    C al & ellu ic la n r li Im C m f u Journal of o n l o a Isakov, J Clin Cell Immunol 2012, S12 l n o r g u y DOI: 0.4172/2155-9899.S12-008 o J Clinical & Cellular Immunology ISSN: 2155-9899Immunology Review Article OpOpenen Access Access PKCθ is a Key Regulator of T-cell Behavior and a Drug Target for T cell- mediated Diseases Noah Isakov* The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences and the Cancer Research Center, Ben Gurion University of the Negev, Beer Sheva, Israel Abstract The protein kinase C-theta (PKCθ) isoform is a member of the calcium-independent novel PKC subfamily of serine/threonine kinases. It is an essential regulatory enzyme in mature T lymphocytes, where it plays a key role in coupling the activated TCR and the CD28 costimulatory receptor to their downstream signaling pathways. TCR/ CD28 engagement induces the translocation of PKCθ to the center of the immunological synapse where it undergoes posttranslational modifications and becomes fully active. The activated PKCθ then initiates signaling pathways leading to the activation of transcription factors, including NF-κB, AP-1 and NF-AT that are essential for the survival, activation and differentiation of T cells. While PKCθ ablation was found to impair a wide range of in vitro responses of T cells, in vivo studies in Prkcq-/- mice revealed that distinct T cell subpopulations differ in their requirements for PKCθ and that PKCθ has a selective role in different immune responses. Thus, PKCθ participates in cellular mechanisms leading to excessive inflammatory responses, autoimmunity, and graftvs host (GvH) disease, but is dispensable for beneficial immune responses against viruses and during graft vs leukemia responses.
    [Show full text]
  • Neuroprotective Versus Tumorigenic Protein Kinase C Activators
    Review Neuroprotective versus tumorigenic protein kinase C activators T.J. Nelson and D.L. Alkon Blanchette Rockefeller Neurosciences Institute, West Virginia University School of Medicine, Morgantown, WV 26506, USA Protein kinase C (PKC) activators possess potent providing neuroprotection. At the same time, unless the neurotrophic and neuroprotective activity, thus indi- time-dependent effects on each PKC isozyme are under- cating potential applications in treating neurodegen- stood, useful drug candidates could be prematurely dis- erative diseases, stroke and traumatic brain injury. missed. To avoid these problems, we need a better Although some activators, such as bryostatin and gni- understanding of the biochemistry of PKC activation. dimacrin, have been tested as antitumor agents, Here, we discuss the current understanding of the basic others, such as phorbol esters, are potent tumor pro- biochemistry of PKC activators and the structural features moters. All PKC activators downregulate PKC at high that distinguish tumor-promoting and neuroprotective concentrations and long application times. However, PKC activators. tumorigenic activators downregulate certain PKC iso- zymes, especially PKCd, more strongly. Tumorigenic Mechanism of PKC activation activators possess unique structural features that PKC activation consists of three steps: phosphorylation, could account for this difference. At concentrations binding to signaling lipids and translocation from the that minimize PKC downregulation, PKC activators cytosol to the membrane (Figure 1). Cytosolic PKC is can improve long-term memory, reduce b-amyloid normally inactive because its pseudosubstrate region, levels, induce synaptogenesis, promote neuronal located on the PKC C1 domain, loops back and binds to repair and inhibit cell proliferation. Intermittent, low the substrate-binding catalytic region located on the C4 concentrations of structurally specific, non-tumori- domain, thereby preventing PKC from binding to any genic PKC activators, therefore, could offer therapeutic substrate proteins.
    [Show full text]
  • Coordinated Activation of the RAC-GAP Β2-CHIMAERIN by an Atypical Proline-Rich Domain and Diacylglcercol Bruce J
    University of Connecticut OpenCommons@UConn UCHC Articles - Research University of Connecticut Health Center Research 1-2013 Coordinated Activation of the RAC-GAP β2-CHIMAERIN by an Atypical Proline-Rich Domain and Diacylglcercol Bruce J. Mayer University of Connecticut School of Medicine and Dentistry Follow this and additional works at: https://opencommons.uconn.edu/uchcres_articles Part of the Medicine and Health Sciences Commons Recommended Citation Mayer, Bruce J., "Coordinated Activation of the RAC-GAP β2-CHIMAERIN by an Atypical Proline-Rich Domain and Diacylglcercol" (2013). UCHC Articles - Research. 185. https://opencommons.uconn.edu/uchcres_articles/185 NIH Public Access Author Manuscript Nat Commun. Author manuscript; available in PMC 2013 July 03. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Nat Commun. 2013 ; 4: 1849. doi:10.1038/ncomms2834. COORDINATED ACTIVATION OF THE RAC-GAP β2-CHIMAERIN BY AN ATYPICAL PROLINE-RICH DOMAIN AND DIACYLGLYCEROL Alvaro Gutierrez-Uzquiza1,*, Francheska Colon-Gonzalez1,*, Thomas A. Leonard2, Bertram J. Canagarajah2, HongBin Wang1, Bruce J. Mayer3, James H. Hurley2, and Marcelo G. Kazanietz1 1Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-6160, USA 2Laboratory of Molecular Biology, National Institutes of Health, Bethesda, MD 20892, USA 3Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT 06030-6403, USA Abstract Chimaerins, a family of GTPase activating proteins (GAPs) for the small G-protein Rac, have been implicated in development, neuritogenesis, and cancer. These Rac-GAPs are regulated by the lipid second messenger diacylglycerol (DAG) generated by tyrosine-kinases such as the epidermal growth factor receptor (EGFR).
    [Show full text]
  • Protein Kinase C and Cancer: What We Know and What We Do Not
    Oncogene (2014) 33, 5225–5237 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW Protein kinase C and cancer: what we know and what we do not R Garg1, LG Benedetti1, MB Abera1, H Wang1, M Abba2 and MG Kazanietz1 Since their discovery in the late 1970s, protein kinase C (PKC) isozymes represent one of the most extensively studied signaling kinases. PKCs signal through multiple pathways and control the expression of genes relevant for cell cycle progression, tumorigenesis and metastatic dissemination. Despite the vast amount of information concerning the mechanisms that control PKC activation and function in cellular models, the relevance of individual PKC isozymes in the progression of human cancer is still a matter of controversy. Although the expression of PKC isozymes is altered in multiple cancer types, the causal relationship between such changes and the initiation and progression of the disease remains poorly defined. Animal models developed in the last years helped to better understand the involvement of individual PKCs in various cancer types and in the context of specific oncogenic alterations. Unraveling the enormous complexity in the mechanisms by which PKC isozymes have an impact on tumorigenesis and metastasis is key for reassessing their potential as pharmacological targets for cancer treatment. Oncogene (2014) 33, 5225–5237; doi:10.1038/onc.2013.524; published online 16 December 2013 Keywords: protein kinase C (PKC); apoptosis; survival; tumorigenesis; metastasis; animal models INTRODUCTION progression and highlights the most recent advances in the field, Protein kinase C (PKC), a prototypical class of serine/threonine particularly using genetically modified mouse models in the kinases, exemplifies specific signaling molecules that link multiple context of specific oncogenic alterations.
    [Show full text]